BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Allogene Therapeutics (ALLO)Allogene TherapeuticsEarnings

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy Strong Execution and Increased Investigator Interest Accelerated 2026 Site

Related news

ALLOAllogene Therapeutics2026-08-04 12:30 EST

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-05-13 20:02 EST

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

LEGNLegend Biotech Corporation2026-08-11 11:00 EST

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

LEGNLegend Biotech Corporation2026-05-12 11:00 EST

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

ALLOAllogene Therapeutics2026-08-12 20:05 EST

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-08-04 12:30 EST

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-07-29 12:30 EST

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

ALLOAllogene Therapeutics2026-07-15 12:30 EST

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLOAllogene Therapeutics2026-05-28 21:02 EST

Allogene Therapeutics Announces Planned CEO Succession

Stock data

Close
2.08 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States